Cibenzoline ( DrugBank: Cibenzoline )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 58 | Hypertrophic cardiomyopathy | 1 |
58. Hypertrophic cardiomyopathy
Clinical trials : 119 / Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194910 | 18/9/2019 | 08/08/2019 | Phase II clinical study of TY-0305 in symptomatic patients with hypertrophic obstructive cardiomyopathy -A pilot study- | Phase II clinical study of TY-0305 in symptomatic patients with hypertrophic obstructive cardiomyopathy -A pilot study- | Symptomatic hypertrophic obstructive cardiomyopathy | Intervention name : TY-0305 INN of the intervention : Cibenzoline Dosage And administration of the intervention : Two tablets orally of TY-0305 50mg twice or three times daily Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | TOA EIYO LTD. | NULL | recruiting | 20 | 75 | BOTH | 10 | Phase 2 | Japan |